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Background: Elevated homocysteine is a cardiovascular risk factor in hyperlipidemia. Transsulfuration pathway
provides an endogenous pathway for homocysteine conversion to antioxidant glutathione (GSH). Salvianolic acid A
(Sal A) contains two molecules of caffeic acid and one molecule of danshensu that is capable of enhancing
homocysteine transsulfuration, which led to the hypothesis that Sal A has activatory effect on transsulfuration
pathway and this effect may have beneficial effects on both homocysteine and redox status in hyperlipidemia.
Methods and results: To test this hypothesis, we developed a rat model of hyperlipidemia induced by high-fat
diet for 16 weeks, during which rats were treated with 1 mg/kg salvianolic acid A (Sal A) for the final 4 weeks.
Activities of key enzymes and metabolite profiling in the transsulfuration pathway revealed that hyperlipidemia led
to elevated plasma homocysteine levels after 16-week dietary treatment, which was associated with reduced
activities of homocysteine transsulfuration enzymes, cystathionine β-synthase (CBS) and cystathionine γ-lyase (CSE).
The impaired transsulfuration pathway prevented homocysteine transsulfuration to cysteine, resulting in cysteine
deficiency and subsequent reduction in GSH pool size. The redox status was altered in the setting of hyperlipidemia
as indicated by GSH/GSSG ratio. Sal A treatment increased hepatic CBS and CSE activities, which was associated
with reduced accumulation in circulating homocysteine levels and attenuated decline in hepatic cysteine content
in hyperlipidemic rats. Sal A also led to an increase in GSH pool size, which subsequently caused a restored
GSH/GSSG ratio. The activatory effect of Sal A on CBS was also observed in normal rats and in in vitro experiment.
Conclusion: Our results suggest that activation of transsulfuration pathway by Sal A is a promising
homocysteine-lowering approach that has beneficial effects on redox homeostasis in hyperlipidemic settings.
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Hypercholesterolemia and hypertriglyceridemia are well-
documented risk factors for the development of cardio-
vascular disease [1]. Homocysteine levels are elevated and
considered as important indicators of atherosclerosis in
hypercholesterolemia and hypertriglyceridemia [2].
Homocysteine is a thiol-containing amino acid, which
suffers two major metabolic fates: remethylation cata-
lyzed by methionine synthase (MS), methylenetetrahy-
drofolate reductase (MTHFR) or betaine-homocysteine
methyltransferases (BHMT) and transsulfuration catalyzed
by cystathionine β-synthase (CBS) leading to cystathionine
[3] (Figure 1). Most of the current homocysteine-lowering
therapies are based on the supplementation of folic acid
that can facilitate the remethylation of homocysteine [4].
However, clinical trials showed that folic acid does not
have beneficial effects on cardiovascular outcomes [5,6]. It
is thus necessary to develop a non-folic acid homocys-
teine-lowering approach for hyperlipidemia, because theFigure 1 Homocysteine metabolic pathways. Abbreviations of the term
catechol-O-methyltransferase; SAHH, S-adenosylhomocysteine hydrolase;
synthase; MTHFR, methylenetetrahydrofolate reductase; SHMT, serine hydroxy
γ-lyase; SAM, S-adenosylmethionine; SAH, S-adenosylhomocysteine; THF, tetra
GGC, γ-glutamylcysteine; GCL, glutamate-cysteine ligase; GS, GSH synthase; GSlack of benefit of homocysteine-lowering therapy suggests
that folic acid-based treatment that is still most widely
used may increase the cardiovascular risk that has already
been elevated in the hyperlipidemic setting.
Besides remethylation, homocysteine can be eliminated
through its transsulfuration [7]. Increasing evidence sup-
port the importance of the transsulfuration pathway in the
maintenance of the redox homeostasis [3,8]. The transsul-
furation pathway provides an endogenous pathway to
utilize homocysteine for production of antioxidant gluta-
thione (GSH). GSH, the most abundant intracellular non-
protein thiol, plays a key role in intracellular defense, and
decreased concentrations of this antioxidant are correlated
with the increased frequency of reactive oxygen species
(ROS)-mediated mitochondrial damage and apoptosis
[9,10]. GSSG is the oxidized form of glutathione, and the
ratio between GSH and GSSG is fundamental for main-
taining the redox status balance and important cellular
functions, such as cell proliferation [11]. Redox imbalances are as follows: MAT, methionine adenosyltransferase; COMT,
BHMT, betaine-homocysteine methyltransferases; MS, methionine
methyltransferase; CBS, cystathionine β-synthase, CSE, cystathionine
hydrofolate; GSH, reduced glutathione; GSSG, oxidized glutathione;
H-Px, glutathione peroxidase; GR, glutathione reductase.
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the onset and progression of the cardiovascular diseases,
such as heart failure [12]. Therefore, transsulfuration path-
way likely promotes the cardiovascular protection via
redox regulation.
In the transsulfuration pathway, CBS is the first and
rate-limiting enzyme for homocysteine conversion to cys-
teine, the availability of the latter controls the rate of GSH
synthesis [13]. Retrospective studies have demonstrated
that some beneficial polyphenols have the capacity to
increase the activity of CBS [14,15]. Salvianolic acid A
(Sal A), an aqueous extract from salvia miltiorrhiza, has
been shown to present wide cardioprotective effects in
myocardial ischemia, endothelial dysfunction and diabetes
with most of the beneficial effects being related to its anti-
oxidant capacity in vivo [16-18]. Previous investigations
supported the most potent protective capacity of Sal A
against oxidative damage among salvia miltiorrhiza-origi-
nated polyphenols including danshensu, salvianolic acid B,
et al., in liver microsomes, hepatocytes and erythrocytes
of rats [19]. Sal A contains 1 molecule of danshensu
(3,4-dihydroxyphenyllactic acid) and 2 molecules of caffeic
acid (3,4-dihydroxycinnamic acid), the latter, a common
coffee polyphenol, is the dehydration product of dan-
shensu. Previous work in our laboratory has demonstrated
that danshensu has potential to lower homocysteine levels
via enhancing the transsulfuration pathway [20], leading
to the possibility that part of the potent antioxidant effect
of Sal A might be due to its activatory effect on transsul-
furation pathway.
Along the lines mentioned above, we reasoned that Sal
A might have activatory effect on transsulfuration pathway
and this effect could show beneficial effects on homocyst-
eine and redox homeostasis in the hyperlipidemic setting.
To test the possibility, we developed a rat model with
hyperlipidemia and treated the rats with Sal A. Con-
centrations of circulating homocysteine as well as its
downstream products and key enzymes activities in the
transsulfuration pathway were measured. The redox status
was measured by determination of GSH/GSSG ratio. Our
results indicate that Sal A indeed activates the transsul-
furation pathway, suggesting a new approach to lower




This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health.
All experimental protocols were approved by Ethics
Committee for Animal Experimentation of China
Pharmaceutical University. All efforts were made to
minimize animal suffering.Chemicals
Unless stated otherwise all chemicals used in these stu-
dies were obtained from Sigma Chemical (Shanghai,
China). Sal A was supplied by Qingfeng Co. Ltd (Jiangxi,
China).
Animals, treatments, and tissue sampling
Male Sprague–Dawley rats (Super-B & K, Ltd., Shanghai,
China) weighing 120–140 g were randomly divided into
four groups with 6 rats per group. In the control group,
normal rats were fed on basic diet prepared for 16 weeks
and were given saline (ip) for the final 4 weeks during
16-week basic diet treatment; in the hyperlipidemia group,
rats were fed on a high-fat diet composed of 56.9% basic
diet, 13% lard, 2% sesame oil, 20% refined sugar, 3% cho-
lesterol, 0.1% sodium cholate and 5% peanuts for 16 weeks
and were given saline (ip) for the final 4 weeks during
16-week high-fat diet treatment; in the control + Sal A
group, normal rats were fed on basic diet prepared for
16 weeks and were given Sal A (1 mg/kg/day, dissolved in
saline, ip) for the final 4 weeks during 16-week basic diet
treatment; in the hyperlipidemia + Sal A group, rats were
fed on a high-fat diet for 16 weeks and were given Sal A
(1 mg/kg/day, dissolved in saline, ip) for the final 4 weeks
during 16-week high-fat diet treatment. All rats were
allowed ad libitum access to food and water throughout
the study. Finally, all these rats were sacrificed. The
plasma was collected, tissues were rapidly removed, snap-
frozen, and stored at −80°C until use. The rats were fasted
for 6 hours before the plasma collection.
Analytical procedures
The plasma homocysteine levels and hepatic cysteine,
GSH, cysteinyl-glycine (Cys-Gly) concentrations were mea-
sured according to the previous method [21]. Rat livers
were homogenized in PBS buffer (0.1 mol/L, pH 7.4) to
prepare a 20% (wt/vol) homogenate for measurement.
S-adenosylmethionine (SAM) and S-adenosylhomocysteine
(SAH) in the liver was measured based on previous method
[22]. Plasma cholesterol, triglycerides, LDL-cholesterol
and hepatic GSSG concentrations were measured spectro-
photometrically by commercial diagnostic kits (Jiancheng
Institute of Biotechnology, Nanjing, China).
The protein concentration was quantified by bicincho-
ninic acid (BCA) assay [23]. The CBS activity assay was
determined by cystathionine formation, as previously des-
cribed with modification [24,25]. Briefly, rat livers were
homogenized in PBS buffer (0.1 mol/L, pH 7.4) to prepare
a 20% (wt/vol) homogenate. After centrifugation, liver
protein supernatant was incubated with reaction mixture
(0.1 mol/L serine, 5 mmol/L EDTA, and 2.5 mmol/L pro-
pargylglycine in Tris buffer (1 mol/L, pH 8.4)), 2.5 mmol/L
pyridoxalphosphate and homocysteine reagent for 1 h
at 37°C. The homocysteine reagent consisted of 0.03 g
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reagent was neutralized by addition of a mixture of
2.57 mL of 4.5 mol/L HCl and 4.43 mL of Tris buffer
(1 mol/L, pH 8.4). The mixture was incubated at 37°C for
60 min and terminated by 50% (vol/vol) trichyperli-
pidemiaoroacetic acid, followed by the centrifugation at
10,000 g for 5 min. The supernatant was mixed with nin-
hydrin solution (0.8% (wt/vol) in glacial acetic acid). The
mixture was boiled for 5 min and cooled on ice for 2 min.
The absorbance of the solution was determined at
455 nm. The activities of glutamate-cysteine ligase (GCL)
and glutathione synthase (GS) were measured together
using the previous method [26]. The activity was deter-
mined from the rate of formation of GSH measured
as described above. The activity of cystathionine γ-lyase
(CSE) in the liver was determined by α-ketobutyrate gene-
ration as description of previous studies with modification
[27]. Rat livers were homogenized in PBS buffer (0.1 mol/L,
pH 7.4) to prepare a 20% (wt/vol) homogenate. After cen-
trifugation, liver protein supernatant was incubated with
reaction mixture containing 32 mmol/L homoserine,
0.1 mmol/L pyridoxalphosphate, 7.5 mmol/L 2-mercap-
toethanol, 7.0 mmol/L EDTA and 0.1 mol/L PBS (pH 7.4).
The incubation was carried at 37°C for 30 min, followed
by adding 20% trichyperlipidemiaoroacetic acid (wt/vol).
The amount of α-ketobutyrate, which was generated
during the enzymatic reaction, was quantified with
3-methyl-2-benzothiazolinone hydrazine hydrochyperlipi-
demiaoride as the description of previous studies [28].
In vitro effect of Sal A on CBS activity
To assess the effect of Sal A on CBS activity in vitro, Sal
A was pre-incubated with normal rat liver homogenate
(20%, w/v in PBS buffer (0.1 mol/L, pH 7.4)) as source
of CBS activity at 37°C for 15 min, afterwards, CBS
activity was determined as described previously. The Sal
A concentrations in homogenate were 0, 0.1, 0.2, 0.5, 1,
2, 4, 10, 25, 50 μmol/L.
Statistical analysis
All data were represented as the means ± SEM. Statistical
analysis was calculated by a one-way ANOVA with
Newman-Keuls test using GraphPad prism 5.0 (GraphPadTable 1 Body weight, plasma cholesterol, triglycerides and LD
Control Control + S
Body weight (g) 351 ± 9 353 ± 7
Cholesterol (mmol/ L) 1.52 ± 0.04 1.53 ± 0.01
Triglycerides (mmol/ L) 1.06 ± 0.04 1.04 ± 0.11
LDL-cholesterol (mmol/ L) 0.93 ± 0.03 1.03 ± 0.03
Data are represented as means ± SEM, n = 6.
*p < 0.05 (vs. control group). **p < 0.01 (vs. control group). ***p < 0.001 (vs. control gr
#p < 0.05 (vs. hyperlipidemia group). ##p < 0.01 (vs. hyperlipidemia group). ###p < 0.00Software, SanDiego, CA, USA). The relationship between
two variables was analyzed by use of linear regression
analysis. The acceptable level of significance was estab-
lished at p < 0.05.Results
Body weight and plasma lipid profile
Following 16 weeks of high-fat diet feeding, body weight
was significantly greater in the hyperlipidemia group
(+21% vs. control group, p < 0.05) (Table 1). In hyperli-
pidemia group, plasma cholesterol, triglycerides as well as
LDL-cholesterol concentrations were significantly higher
than in control group (p < 0.05). After Sal A treatment, in
hyperlipidemic rats, no significant changes were observed
in body weight, cholesterol and triglycerides levels in
plasma. In contrast, hyperlipidemia-induced elevation of
plasma LDL-cholesterol levels was reduced by Sal A treat-
ment (−20% vs. hyperlipidemia group, p < 0.001).Plasma homocysteine levels and activity profile of key
enzymes for homocysteine transsulfuration in the liver
Plasma homocysteine level was elevated in hyperlipidemic
rats (12.78 ± 0.28 μmol/L) compared with control rats
(10.78 ± 0.20 μmol/L, p < 0.001) (Figure 2A). The enzyme
activity profiling for homocysteine transsulfuration in the
liver where the lipid metabolism and homocysteine me-
tabolism take place showed that hyperlipidemia led to a
significant decrease in CBS activity (−44% vs. control
group, p < 0.01) (Figure 2B) and CSE activity (−19% vs.
control group, p < 0.001) (Figure 2C) in the liver, indica-
ting impaired homocysteine transsulfuration to cysteine.
Consistently, cysteine content was reduced in hyperli-
pidemia group (0.18 ± 0.01 μmol/g liver) compared
with control group (0.33 ± 0.03 μmol/g liver, p < 0.001)
(Figure 3C).
In hyperlipidemic rats, Sal A treatment caused enhanced
activities of hepatic CBS (+2.2-fold vs. hyperlipidemia
group, p < 0.01) and CSE (+7% vs. hyperlipidemia group,
p < 0.05), which was accompanied by a reduction in
plasma homocysteine levels (−17% vs. hyperlipidemia
group, p < 0.05) and an increase in hepatic cysteine con-
centrations (+33% vs. hyperlipidemia group, p < 0.05).L-cholesterol concentrations
al A Hyperlipidemia Hyperlipidemia + Sal A
425 ± 19* 423 ± 21
2.92 ± 0.16*** 2.64 ± 0.20
1.50 ± 0.12* 1.37 ± 0.12
1.52 ± 0.09*** 1.21 ± 0.05###
oup).
1 (vs. hyperlipidemia group).
Figure 2 Effect of Sal A on plasma homocysteine concentrations and hepatic homocysteine transsulfuration activity. Plasma
homocysteine levels (A), and hepatic activities of homocysteine transsulfuration enzymes, CBS (B) and CSE (C), in the normal rats (control) and
hyperlipidemic rats after 4-week Sal A treatment (1 mg/kg/day, ip). Bars represent means ± SEM, n = 6. (D) In vitro effect of Sal A on CBS activity:
liver homogenate as source of CBS activity was incubated with Sal A at the dose of 0.1, 0.2, 0.5, 1, 2, 4, 10, 25, 50 μmol/L at 37°C for 15 min.
Control represents the CBS activity without Sal A. Bars represent means ± SEM, n = 8. *p < 0.05 (vs. control group). **p < 0.01 (vs. control group).
***p < 0.001 (vs. control group). #p < 0.05 (vs. hyperlipidemia group). ##p < 0.01 (vs. hyperlipidemia group). ###p < 0.001 (vs. hyperlipidemia group).
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activity of hepatic CBS was increased by 37% (p < 0.01)
whereas CSE activity was unchanged compared with un-
treated normal rats. Meanwhile, hepatic cysteine content
was increased by 26% (p < 0.01) whereas plasma homo-
cysteine concentrations showed no statistically difference
as compared with untreated controls.
Correlation analysis showed that hepatic CBS activity
was positively correlated with hepatic cysteine concen-
trations (r = 0.59, p < 0.01, the curve was not shown).
Sal A caused an increase in CBS activity in in vitro
experiment
The Sal A increased CBS activity at the concentration
of 0.2, 0.5, 1, 2, 4 μmol/L with significance (p < 0.05)
(Figure 2D). The Sal A activated about 25% of the en-
zyme activity when incubated with liver homogenatefor 15 min at 37°C at the concentration of 0.5 μmol/L
(p < 0.001).
Hepatic redox status
The glutathione status (GSH/GSSG ratio), which accu-
rately reflects intracellular redox status, was used as indi-
cator of oxidative stress in this study [29]. A reduced
GSH/GSSG ratio was observed in the liver of hyperlipi-
demic rats (−39% vs. control group, p < 0.01) (Figure 4A).
Together with this, GSH concentration was also decreased
(−37% vs. control group, p < 0.001) (Figure 3A) whereas
GSSG concentrations were indistinguishable between con-
trol (0.15 ± 0.01 μmol/g liver) and hyperlipidemia group
(0.17 ± 0.01 μmol/g liver). GSH synthesis depends on the
availability of its rate-limiting precursor cysteine [30].
Deficiency of cysteine content (−44% vs. control group,
p < 0.001) (Figure 3C) and unchanged GSH synthetic
Figure 3 Effects of Sal A on the concentrations of GSH and its relevant metabolites. GSH concentrations (A) and its correlation with CBS
activity (B) in the liver of normal rats (control) and hyperlipidemic rats after 4-week Sal A treatment (1 mg/kg/day, ip). Concentrations of GSH
precursor cysteine (C), GSH synthetic capacity (D) as well as concentrations of GSH extracellular metabolite Cys-Gly (E) in the liver of normal rats
(control) and hyperlipidemic rats after 4-week Sal A treatment (1 mg/kg/day, ip). Bars represent means ± SEM, n = 6. *p < 0.05 (vs. control group).
**p < 0.01 (vs. control group). ***p < 0.001 (vs. control group). #p < 0.05 (vs. hyperlipidemia group). ##p < 0.01 (vs. hyperlipidemia group).
###p < 0.001 (vs. hyperlipidemia group).
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tion in the liver of hyperlipidemia group. Moreover, the
hepatic concentration of Cys-Gly, an extracellular GSH
metabolite, was elevated in hyperlipidemia group (+71% vs.
control group, p < 0.001) (Figure 3E), which indicated an
increased loss of GSH from the cell.
In response to Sal A treatment, cysteine content and
enhanced GSH synthetic capacity were increased in both
control (cysteine content: +26%, p < 0.01; GSH synthetic
capacity: +46%, p < 0.01) and hyperlipidemia group
(cysteine content: +33%, p < 0.05; GSH synthetic capacity:
+41%, p < 0.01), which occurred with a decrease in
the Cys-Gly concentration in the hyperlipidemia group
(−35%, p < 0.001). This suggested enhanced GSH synthesisin both control and hyperlipidemia group and reduced
GSH efflux from hepatocytes in the hyperlipidemia
group after Sal A treatment. Consistently, GSH concen-
trations was elevated in the liver of both control (+17%,
p < 0.01) and hyperlipidemia (+38%, p < 0.001) groups.
Meanwhile, together with increased GSH levels, hyper-
lipidemia group showed a decline in the GSSG levels
(−31%, p < 0.05) and an elevation in GSH/GSSG ratio
(+83%, p < 0.001) after Sal A treatment, which indicated
attenuated oxidative stress.
Correlation analysis showed that CBS activity was
strongly and positively correlated with GSH concentra-
tions (r = 0.79, p < 0.0001) (Figure 3B) and GSH/GSSG
ratio (r = 0.81, p < 0.0001) (Figure 4B).
Figure 4 Effect of Sal A on redox status. Hepatic GSH/GSSG ratio (A) as well as its correlation with CBS activity (B) in the normal rats (control) and
hyperlipidemic rats after 4-week Sal A treatment (1 mg/kg/day, ip). Bars represent means ± SEM, n = 6. *p < 0.05 (vs. control group). **p < 0.01
(vs. control group). ***p < 0.001 (vs. control group). #p < 0.05 (vs. hyperlipidemia group). ##p < 0.01 (vs. hyperlipidemia group). ###p < 0.001
(vs. hyperlipidemia group).
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A decrease in SAM/SAH ratio was predictive of reduced
methylation capacity in hyperlipidemia group (−43% vs.
control group, p < 0.01) (Table 2). After Sal A treatment,
SAM/SAH ratio was unchanged in the hyperlipidemia
group whereas this ratio was decreased in the control
group (−29%, p < 0.01).
Discussion
Elevated plasma homocysteine level is a risk factor of
atherogenesis [31]. In the present study, we found that
Sal A was capable to lower elevated plasma homocys-
teine levels in the hyperlipidemic setting. This effect,
which was relevant to the enhanced homocysteine trans-
sulfuration, was due to the stimulatory effect of Sal A on
CBS activity, the latter was also responsible for the alle-
viation of the redox imbalance in hyperlipidemia.
Hyperlipidemia and elevated plasma homocysteine levels
as well as cysteine deficiency
In our experiment, plasma homocysteine was elevated
after 16-week high-fat dietary treatment as compared withTable 2 The methylation status in the liver
Control Control + Sal A
SAM (nmol/g liver) 112.8 ± 10.8 83.0 ± 4.8**
SAH (nmol/g liver) 26.7 ± 1.7 27.8 ± 1.4
SAM/SAH 4.2 ± 0.4 3.0 ± 0.2**
Data are represented as means ± SEM, n = 6.
*p < 0.05 (vs. control group). **p < 0.01 (vs. control group). ***p < 0.001 (vs. control gr
#p < 0.05 (vs. hyperlipidemia group). ##p < 0.01 (vs. hyperlipidemia group). ###p < 0.00normal controls. Activity profiling of transsulfuration en-
zymes suggested that impaired transsulfuration pathway
characterized by reduced activities of CBS and CSE
brought about depressed conversion of homocysteine to
cysteine along the transsulfuration pathway, consequently
leading to upstream homocysteine accumulation and
downstream cysteine deficiency in the hyperlipidemia.
Our results were consistent with previous studies and
were supported indirectly by the studies that focused on
inborn CBS deficiency [32]. CBS deficiency led to mar-
kedly homocysteine accumulation and severely decreased
levels of cystathionine and cysteine, which was due to im-
paired homocysteine removal through the transsulfuration
pathway [32]. Our findings in a hyperlipidemia model
were consistent with previous studies which reported that
18-week high-fat feeding could cause hyperhomocysteine-
mia accompanied by cysteine deficiency, led to the specu-
lation that the transsulfuration pathway was affected [33].
Down-regulated activities of CBS and CSE of the pathway
confirmed the speculation and therefore led to their con-
clusion that high-fat-induced down-regulation of hepatic
transsulfuration activity caused plasma homocysteineHyperlipidemia Hyperlipidemia + Sal A
64.2 ± 5.0*** 60.3 ± 5.5
27.9 ± 1.5 23.3 ± 1.6
2.4 ± 0.3** 2.6 ± 0.3
oup).
1 (vs. hyperlipidemia group).
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risk of cardiovascular disease associated with the con-
dition [33].
Hyperlipidemia and enhanced oxidative stress
Oxidative stress was enhanced in the hyperlipidemic
rats, which was indicated by reduced GSH pool size and
GSH/GSSG ratio.
GSH plays a central role in the antioxidant defence of
cells against oxidative stress [34]. The GSH intracellular
concentration reflects a dynamic balance between the syn-
thesis and consumption of GSH within the cell and loss
through efflux [35]. In the setting of hyperlipidemia, con-
spicuous reduction in GSH content in the liver was ob-
served, which was accompanied by the reduction in the
concentration of cysteine-the rate limiting precursor of
GSH, suggesting that reduced availability of cysteine led to
impaired GSH production, and subsequent decreased
GSH pool size. The hepatic concentration of Cys-Gly, an
extracellular metabolite of GSH degradation catalyzed by
γ-glutamyl transpeptidase [36], was increased in hyperlip-
idemic rats compared with normal ones, indicating an in-
creased secretion or GSH loss from the hepatocytes,
followed by GSH degradation. This was also responsible
for GSH depletion in hyperlipidemia.
In our study, no significant difference in hepatic GSSG
concentrations was found between hyperlipidemic and
normal rats. Under oxidative stress conditions, ROS are
reduced by GSH with concomitant formation of the
GSSG [37]. However, GSSG did not accumulation in the
setting of hyperlipidemia. To maintain the cellular redox
balance, GSSG is rapidly and efficiently exported out
of the cell by ATP-dependent transport proteins under
conditions of oxidative stress [38]. This would provide
an explanation for unchanged GSSG content in this
study.
The transsulfuration pathway-the link between redox
imbalance and homocysteine elevation in the setting of
hyperlipidemia
GSH synthesis is dependent on the availability of cysteine
[30], the latter is the downstream product of homocys-
teine in its transsulfuration. Actually, the effect of trans-
sulfuration pathway on GSH concentrations is more than
its effect on GSH synthesis, but also the GSH efflux from
the cell. The loss of GSH through the membrane may in
turn depend on membrane oxidative stress, because oxi-
dative stress causes lipid peroxidation of cell membrane,
leading to altered membrane permeability and transport
functions and consequently increased GSH efflux [36].
The decrease of antioxidant GSH synthesis could make
contributions to oxidative stress that in turn led to in-
creased GSH loss to the extracellular space. The involve-
ment of transsulfuration regulated GSH generation andexportation strengthens the importance of the role that
transsulfuration pathway played in the redox control.
Our data showed that hyperlipidemia-induced trans-
sulfuration impairment blocked the homocysteine con-
version to cysteine, which led to not only upstream
accumulation of homocysteine, but also downstream
deficiency of cysteine and subsequent reduction of anti-
oxidant GSH synthesis. This would further reduce the
hepatic GSH content by means of enhancing the efflux
of GSH from the intercellular space, and then further
aggravate the redox imbalance.
In the setting of hyperlipidemia, the pathological effect
of transsulfuration pathway on redox status is not that
simple, because in normal physiological settings, the flux
of homocysteine to GSH through the transsulfuration
pathway can be compensatively enhanced in response to
the oxidative stress in order to maintain the oxidant/anti-
oxidant balance whereas antioxidant treatment elicit the
opposite effect on transsulfuration pathway [8]. However,
in the setting of hyperlipidemia, GSH depletion caused by
disturbed transsulfuration could lead to the oxidant/anti-
oxidant imbalance on its own, and the impaired transsul-
furation could cause the loss of the compensatory GSH
synthesis in response to oxidative stress, which would lead
to further oxidative stress.
Along the lines above, transsulfuration pathway is
likely to be a potential target for homocysteine-lowering
and redox-rebalancing approach in the hyperlipidemic
setting.
Homocysteine accumulation was reduced in response to
Sal A treatment in hyperlipidemia–the activatory effect of
Sal A on CBS activity
In the transsulfuration pathway, CBS catalyzes the initial
and rate-limiting step for homocysteine transsulfuration
pathway [39]. The CBS activatory capacity was previously
found in catechin and wind polyphenols [14,15]. In this
study, after Sal A treatment, elevated plasma homocys-
teine levels and reduced hepatic cysteine concentrations
returned toward normal when the activities of CBS and
CSE were increased in hyperlipidemic rats. In addition,
the activatory effect of Sal A on the CBS activity was
found not only in the hyperlipidemic rats but also in the
liver homogenate in vitro, and in the normal rats. These
results suggested that Sal A enhanced the homocysteine
removal via its transsulfuration to cysteine in hyperlipi-
demic rats by means of increasing CBS activity.
However, normal rats showed unchanged homocysteine
concentration in the plasma, even though the CBS was
activated and cysteine concentration was elevated after
the Sal A treatment. Like other polyphenols, Sal A can
accept methyl groups from SAM and cause an elevation
of homocysteine during the methionine-homocysteine
cycle (Figure 1) [20]. It is likely that the amount of
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homocysteine conversion to cysteine via transsulfuration
pathway was comparable, leading to unchanged homo-
cysteine concentration in normal rats after Sal A treat-
ment. In contrast, the Sal A methylation can be inhibited
because of the diminished SAM and consequent hypome-
thylation in hyperlipidemic rats (Table 2). In this circum-
stance, it is even more significant for the elimination of
homocysteine through transsulfuration pathway than that
of increase caused by the methylation of Sal A.
In this study, we found that Sal A also had potential to
lower homocysteine levels via enhancing the transsulfura-
tion of homocysteine like danshensu [20]. Sal A is com-
posed of danshensu and its structural analog caffeic acid,
indicating that the activatory effect of Sal A on homo-
cysteine transsulfuration is probably conferred by its dan-
shensu-containing structure. In retrospective, the exact
step of transsulfuration pathway at which danshensu acts
has not been tested and our current study revealed that
Sal A activated CBS, the key enzyme for homocysteine
transsulfuration pathway, to achieve its homocysteine-
lowering effect. In addition, previous studies focused upon
the effect of danshensu on homocysteine were conducted
in a rat model of hyperhomocysteinemia that was induced
by prolonged methionine dosing [20]. In that pathological
model, plasma homocysteine accumulation was mainly
attributed to increased homocysteine production from
methionine but not impaired homocysteine conversion to
cysteine. The effects of danshensu on impaired transsul-
furation are unclear. Our present study showed that Sal A
was capable to reduce the homocysteine elevation caused
by transsulfuration block in hyperlipidemia.
Oxidative stress was ameliorated in response to Sal A in
hyperlipidemia–an increase in concentrations of
downstream products of homocysteine in the
transsulfuration pathway
Sal A led to ameliorated oxidative stress that was reflected
by elevations of GSH/GSSG ratio in the hyperlipidemic
rats. This elevation was due to increased GSH content
and decreased GSSG content after Sal A treatment. In Sal
A treated normal controls, GSH concentration was also
elevated whereas GSH/GSSG ratio tended to increase but
not significantly. Moreover, the GSH concentration and
its ratio with GSSG concentration were strongly, and posi-
tively, correlated with hepatic CBS activity, indicating that
Sal A-induced GSH increase and subsequent alteration in
GSH/GSSG ratio was associated with its activatory effect
on CBS activity. Consistently, our data showed that to-
gether with the increase of GSH content, cysteine concen-
trations as well as the CBS and GSH synthetic activities,
were also increased in both hyperlipidemic and normal
rats whereas the Cys-Gly concentrations were declined in
hyperlipidemic rats after Sal A treatment. It was suggestedthat Sal A enhanced GSH synthesis due to its activatory
effect on CBS and consequent homocysteine conversion
to cysteine, which subsequently enhanced antioxidant de-
fence and prevented redox-induced GSH loss, leading to
further increase in GSH pool size and GSH/GSSG ratio in
hyperlipidemic rats. This beneficial effects of Sal A on
redox homeostasis was consistent with previous studies
showing that Sal A exerted its protective effects against
oxidative stress via reducing ROS accumulation in both
animal and hepatocyte culture models [40,41]. The effect
of Sal A on transsulfuration pathway and this pathway-
dependent GSH synthesis found in this study provides a
new sight into the antioxidant effect of Sal A besides its
catechol structures and is suggested to be one of the mul-
tiple mechanisms accounting for the potential beneficial
effects of Sal A.
Limitations
In this study, we have demonstrated that Sal A has activa-
tory capacity on homocysteine transsulfuration to antioxi-
dant GSH. Despite the well documented relationship
between oxidative stress and cardiovascular diseases [42],
whether the Sal A treatment would eventually improve
cardiovascular outcomes in the setting of hyperlipidemia
is unknown, although the wide cardioprotective effects of
Sal A have been studied and confirmed previously in myo-
cardial infarction, and other pathological settings [16,43].
The possibility for Sal A to be used as a cardioprotective
homocysteine-lowering therapy in hyperlipidemia needs
to be further investigated.
Conclusions
In conclusion, the present study supports the involvement
of impaired transsulfuration pathway in the hyperlipi-
demia-induced homocysteine accumulation and redox im-
balance. Furthermore, our data demonstrates that Sal A
has activatory capacity on CBS activity and this effect
makes it a promising homocysteine-lowering approach
with beneficial effects on redox status in the setting of
hyperlipidemia.
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